Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

TScan Therapeutics (TCRX) EBITDA Margin (2020 - 2025)

TScan Therapeutics (TCRX) has disclosed EBITDA Margin for 6 consecutive years, with 929.41% as the latest value for Q4 2025.

  • On a quarterly basis, EBITDA Margin rose 459119.0% to 929.41% in Q4 2025 year-over-year; TTM through Dec 2025 was 1253.68%, a 353400.0% increase, with the full-year FY2025 number at 1257.31%, up 326854.0% from a year prior.
  • EBITDA Margin was 929.41% for Q4 2025 at TScan Therapeutics, up from 1669.74% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 296.17% in Q4 2023 to a low of 6364.55% in Q2 2024.
  • A 5-year average of 1620.57% and a median of 619.62% in 2022 define the central range for EBITDA Margin.
  • Peak YoY movement for EBITDA Margin: tumbled -558279bps in 2024, then surged 459119bps in 2025.
  • TScan Therapeutics' EBITDA Margin stood at 497.62% in 2021, then dropped by -21bps to 602.55% in 2022, then soared by 51bps to 296.17% in 2023, then tumbled by -1764bps to 5520.6% in 2024, then skyrocketed by 83bps to 929.41% in 2025.
  • Per Business Quant, the three most recent readings for TCRX's EBITDA Margin are 929.41% (Q4 2025), 1669.74% (Q1 2025), and 5520.6% (Q4 2024).